British pharmaceutical giant AstraZeneca has announced a research programme to develop a new generation of medicines to treat the genetic causes of many debilitating diseases, such as diabetes, heart disease and many cancers.

英國制藥巨頭阿斯利康制藥日前宣布一項(xiàng)研究計(jì)劃，開發(fā)新一代藥物，治療許多因遺傳因素引起的使人衰弱的疾病，例如糖尿病、心臟病和不少癌癥。

AstraZeneca said it plans to make use of so-called CRISPR genome-editing technology for key therapeutic areas including oncology. The technology enables researchers to “edit” the genes of certain cells relatively quickly and accurately.

阿斯利康稱，其計(jì)劃是在包括腫瘤學(xué)的重要治療領(lǐng)域利用被稱作CRISPR的“基因剪刀”技術(shù)。“基因剪刀”技術(shù)使得研究人員可以相對快而準(zhǔn)地“編輯”一些細(xì)胞的基因。

例句：

Some companies are using gene-editing techniques to change the plant's existing DNA rather than insert foreign genes.

一些公司正使用“基因剪刀”技術(shù)來改變植物現(xiàn)在的DNA，而不是插入外來基因。

（中國日報(bào)網(wǎng)英語點(diǎn)津 Bernard）